




Figure S13. Gating strategy of TRPM2 and CD38 using primary TRPM2 antibody (1:5) at 2hr/1hr.

Additional file 13: **Figure S13.** Gating strategy of TRPM2 and CD38 using primary TRPM2 antibody (1:5) at 2hr/1hr. **(a)** Lymphocyte populations were identified using forward and side scatter dot plots. **(b)** Duration of cell acquirement was measured followed by **(c)** cell viability after 7-AAD staining. **(d)** CD3⁺ cells were excluded and only **(e)** CD3⁻ lymphocytes were further used to characterise NK cells by CD56. **(f)** CD3⁻/CD56⁺ NK cells were sorted into CD56^{Bright}CD16^{Dim/-} and CD56^{Dim}CD16^{+/+} NK cell subsets using CD56 and CD16. TRPM2 surface expression was measured on **(g)** CD56^{Dim}CD16^{+/+} and **(h)** CD56^{Bright}CD16^{Dim/-} NK cell subsets. Dual surface expression of TRPM2 and CD38 was furthermore assessed on **(i)** CD56^{Bright}CD16^{Dim/-} and **(j)** CD56^{Dim}CD16^{+/+} NK cell subsets. Data are represented as mean $\pm$ SEM. (PDF 46kb).